| Robert D Moore, MD | |
|
7822 Davenport St, Omaha, NE 68114-3629 | |
| (402) 391-4855 | |
| (402) 391-6818 |
| Full Name | Robert D Moore |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 30 Years |
| Location | 7822 Davenport St, Omaha, Nebraska |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316039340 | NPI | - | NPPES |
| 050060315 | Other | RR MEDICARE | |
| 270614 | Other | MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 20808 (Nebraska) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| The Nebraska Methodist Hospital | Omaha, NE | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Anesthesia West Pc | 4789596834 | 60 |
News Archive
ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, announces that data from the second Phase III trial of microplasmin (TG-MV-007) for the non-surgical treatment of vitreomacular adhesion (VMA), are to be presented at the 28th Annual Meeting of the American Society of Retina Specialists (ASRS) and the 10th EURETINA Congress.
CANCER is on the rise and the need to be empathetic when giving a patient their diagnosis and throughout treatment is imperative.
Researchers studying yeast cells have identified a metabolic enzyme as a potential therapeutic target for treating Huntington's disease, a fatal inherited neurodegenerative disorder for which there is currently no effective treatment. The group, whose results appear in the May issue of Nature Genetics, includes researchers from the University of Washington School of Medicine in Seattle and the University of Maryland School of Medicine in Baltimore.
Bayer Inc. today responded to Professor Marvin Meyer's letter to the editor, entitled: "Critical questions concerning the validity of the Bayer study report of differences in bioavailability between 60 mg of nifedipine osmotic push-pull systems after fasted and fed administration" and published in the online edition of the International Journal of Clinical Pharmacology and Therapeutics. Bayer responded to the clinical relevance of the differences in formulation and dissolution behaviour and the delayed absorption of Mylan's extended release nifedipine.
The oral microbiota of 3-month old infants is distinguishable by whether they are breast- or formula-fed, show study findings.
› Verified 7 days ago
| Entity Name | Anesthesia West Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508899568 PECOS PAC ID: 4789596834 Enrollment ID: O20031105000662 |
News Archive
ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, announces that data from the second Phase III trial of microplasmin (TG-MV-007) for the non-surgical treatment of vitreomacular adhesion (VMA), are to be presented at the 28th Annual Meeting of the American Society of Retina Specialists (ASRS) and the 10th EURETINA Congress.
CANCER is on the rise and the need to be empathetic when giving a patient their diagnosis and throughout treatment is imperative.
Researchers studying yeast cells have identified a metabolic enzyme as a potential therapeutic target for treating Huntington's disease, a fatal inherited neurodegenerative disorder for which there is currently no effective treatment. The group, whose results appear in the May issue of Nature Genetics, includes researchers from the University of Washington School of Medicine in Seattle and the University of Maryland School of Medicine in Baltimore.
Bayer Inc. today responded to Professor Marvin Meyer's letter to the editor, entitled: "Critical questions concerning the validity of the Bayer study report of differences in bioavailability between 60 mg of nifedipine osmotic push-pull systems after fasted and fed administration" and published in the online edition of the International Journal of Clinical Pharmacology and Therapeutics. Bayer responded to the clinical relevance of the differences in formulation and dissolution behaviour and the delayed absorption of Mylan's extended release nifedipine.
The oral microbiota of 3-month old infants is distinguishable by whether they are breast- or formula-fed, show study findings.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Robert D Moore, MD 7822 Davenport St, Omaha, NE 68114-3629 Ph: (402) 391-4855 | Robert D Moore, MD 7822 Davenport St, Omaha, NE 68114-3629 Ph: (402) 391-4855 |
News Archive
ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, announces that data from the second Phase III trial of microplasmin (TG-MV-007) for the non-surgical treatment of vitreomacular adhesion (VMA), are to be presented at the 28th Annual Meeting of the American Society of Retina Specialists (ASRS) and the 10th EURETINA Congress.
CANCER is on the rise and the need to be empathetic when giving a patient their diagnosis and throughout treatment is imperative.
Researchers studying yeast cells have identified a metabolic enzyme as a potential therapeutic target for treating Huntington's disease, a fatal inherited neurodegenerative disorder for which there is currently no effective treatment. The group, whose results appear in the May issue of Nature Genetics, includes researchers from the University of Washington School of Medicine in Seattle and the University of Maryland School of Medicine in Baltimore.
Bayer Inc. today responded to Professor Marvin Meyer's letter to the editor, entitled: "Critical questions concerning the validity of the Bayer study report of differences in bioavailability between 60 mg of nifedipine osmotic push-pull systems after fasted and fed administration" and published in the online edition of the International Journal of Clinical Pharmacology and Therapeutics. Bayer responded to the clinical relevance of the differences in formulation and dissolution behaviour and the delayed absorption of Mylan's extended release nifedipine.
The oral microbiota of 3-month old infants is distinguishable by whether they are breast- or formula-fed, show study findings.
› Verified 7 days ago
Stephanie Franco, CRNA Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 6901 N 72nd St, Omaha, NE 68122 Phone: 402-572-2121 | |
Dr. Joseph M Kalamaja, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: Emile 42nd St, Omaha, NE 68198 Phone: 402-559-4081 Fax: 402-559-7372 | |
Wesley K Hubka, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 7822 Davenport St, Omaha, NE 68114 Phone: 402-391-4855 Fax: 402-391-6818 | |
Dr. Cam E Enarson, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 2500 California Plz, Omaha, NE 68178 Phone: 402-280-5823 | |
Dr. Kimberly A Hanson, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: Children's Hospital - Anesthesiology, 8200 Dodge Street, Omaha, NE 68114 Phone: 402-955-4303 Fax: 402-955-4300 | |
Marvin Graves Henderson, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 6901 N 72 Street, Omaha, NE 68122 Phone: 402-778-9738 Fax: 402-334-2849 | |
John Ashton Heckathorn Ii, DO Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 7500 Mercy Rd Ste 1355, Omaha, NE 68124 Phone: 402-717-4866 |